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Abstract
Background: The polymerase chain reaction (PCR) has been proposed for diagnosis, staging and post-treatment follow-up
of sleeping sickness but no large-scale clinical evaluations of its diagnostic accuracy have taken place yet.
Methodology/Principal Findings: An 18S ribosomal RNA gene targeting PCR was performed on blood and cerebrospinal
fluid (CSF) of 360 T. brucei gambiense sleeping sickness patients and on blood of 129 endemic controls from the Democratic
Republic of Congo. Sensitivity and specificity (with 95% confidence intervals) of PCR for diagnosis, disease staging and
treatment failure over 2 years follow-up post-treatment were determined. Reference standard tests were trypanosome
detection for diagnosis and trypanosome detection and/or increased white blood cell concentration in CSF for staging and
detection of treatment failure. PCR on blood showed a sensitivity of 88.4% (84.4–92.5%) and a specificity of 99.2% (97.7–
100%) for diagnosis, while for disease staging the sensitivity and specificity of PCR on cerebrospinal fluid were 88.4% (84.8–
91.9%) and 82.9% (71.2–94.6%), respectively. During follow-up after treatment, PCR on blood had low sensitivity to detect
treatment failure. In cerebrospinal fluid, PCR positivity vanished slowly and was observed until the end of the 2 year follow-
up in around 20% of successfully treated patients.
Conclusions/Significance: For T.b. gambiense sleeping sickness diagnosis and staging, PCR performed better than, or similar
to, the current parasite detection techniques but it cannot be used for post-treatment follow-up. Continued PCR positivity
in one out of five cured patients points to persistence of living or dead parasites or their DNA after successful treatment and
may necessitate the revision of some paradigms about the pathophysiology of sleeping sickness.
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Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is
caused by Trypanosoma brucei (T. b.) gambiense or T. b. rhodesiense and
transmitted by tsetse flies. The disease is endemic in several
countries in sub-Saharan Africa and usually found in remote rural
areas. The Democratic Republic of the Congo (DRC) has the
highest prevalence of T. b. gambiense HAT, with 8,000 to 25,000
cases diagnosed annually between 1997 and 2006 [1]. In the
absence of prophylactic drugs or vaccines, disease control relies
heavily on accurate diagnosis and effective treatment of patients.
Diagnosis of T. b. gambiense HAT is generally based on serological
screening of individuals followed by confirmation through parasite
detection in lymph node aspirates or blood [2]. The disease
progresses over two stages, the haemolymphatic (first stage) and
the meningo-encephalitic phase (second stage), which require
different drug regimens [3]. Hence, accurate staging of the disease
is important for the therapeutic decision and done by microscopic
analysis of the cerebrospinal fluid (CSF) [4]. The World Health
Organization recommends a follow-up after treatment of 2 years
before confirmation of definite cure, which is defined as the
absence of trypanosomes, normalized white blood cell count in
CSF and normalization of clinical signs [5].
In the past two decades, a wide range of different polymerase
chain reaction (PCR) tests has been developed for trypanosome
detection and identification [6]. PCR has frequently been
presented as promising in HAT patient diagnosis, staging and
post-treatment follow-up. However, very few PCR approaches
have been evaluated on a large number of clinical specimens and
none has been evaluated for detection of treatment failure in a
www.plosntds.org 1 February 2011 | Volume 5 | Issue 2 | e972prospective longitudinal study. Here we present the results of PCR
on a series of 360 T. b. gambiense HAT patients who were enrolled
in a 2-year prospective cohort. We evaluate the diagnostic
accuracy of PCR in diagnosis, staging and detection of treatment
failure.
Methods
Ethics statement
Samples from HAT patients were collected within a prospective
observational study (THARSAT) [7]. The Commission for
Medical Ethics of Institute of Tropical Medicine, Antwerp,
Belgium and the Ethical Commission of the Ministry of Public
Health, DRC approved this study. Negative control samples were
collected within the TRYLEIDIAG study, which was approved by
the commission for Medical Ethics of the University of Antwerp,
Belgium and the Ethical Commission of the Ministry of Health
DRC. All participants had given their written informed consent
before inclusion into the study.
Study participants
Human African trypanosomiasis patients were prospectively
enrolled in the hospital of Mbuji Mayi, Kasai Province, DRC as
described earlier [7] using the following inclusion criteria:
trypanosomes in lymph node aspirate, blood or CSF; $12 years
old; and living within a 100 km perimeter around Mbuji Mayi.
Exclusion criteria were: pregnancy; no guarantee for follow-up;
moribund condition; hemorrhagic CSF or; concurrent serious
illness (tuberculosis, bacterial or cryptococcal meningitis). The
cohort consisted of primary HAT cases (never treated previously
for HAT) and retreatment HAT cases (previously treated for
HAT, but with reappearance of trypanosomes in CSF at
inclusion). All cases were treated according to the national
guidelines [7]. First stage patients were treated with pentamidine,
second stage cases with melarsoprol, eflornithine, or melarsoprol/
nifurtimox, melarsoprol/eflornithine or eflornithine/nifurtimox
combination therapy [7]. Patients were monitored for treatment
outcome over 2 years.
Healthy endemic controls were recruited in the hospital of
Mbuji-Mayi and at the University of Kinshasa [8]. A person was
considered as a negative control when there was no clinical
suspicion for HAT, no history of HAT, CATT was negative, and
no trypanosomes were detected in blood.
Reference standards
Sensitivity of PCR for HAT diagnosis was estimated in patients
with a primary episode of HAT that was parasitologically
confirmed by microscopic examination. Trypanosomes were
detected by sequential examination of lymph node aspirate, blood
examination by the capillary centrifugation technique or the mini-
anion exchange centrifugation technique or examination of the
CSF by modified single centrifugation [9–11].
The reference standard for staging of HAT was examination of the
CSF on white blood cell (WBC) count and presence of trypanosomes
by modified single centrifugation [10,11]. Patients with 0–5 WBC/ml
and no trypanosomes in CSF were classified in first stage, those with
.5W B C / ml and/or trypanosomes in CSF in second stage.
To determine HAT treatment outcome, examinations of CSF
and/or blood of HAT patients were performed at 3, 6, 12, 18, and
24 months after treatment [12]. Treatment outcomes are
described in detail elsewhere [7]. Briefly, the outcome was
treatment failure, if during follow-up one of the following events
occurred: 1u trypanosomes reappeared (relapse); 2u the CSF WBC
increased by .30 cells/ml compared with the lowest previous
count (probable relapse) or was higher than 20 cells/mla t2 4
months (probable relapse); 3u occurrence of clinical signs requiring
rescue treatment in the opinion of the physician in charge
(probable relapse), or ; 4u death possibly related to HAT
(interviews with family members revealed that there was no
clinical improvement after HAT treatment and before the patient
died). Cases that were lost to follow-up, died during treatment or
died over the following 2 years from non-HAT related causes were
considered without outcome and excluded. The treatment
outcome was cure, if none of the above described events occurred.
All examinations were done by laboratory technicians experi-
enced in HAT diagnosis.
PCR
From HAT patients, blood and CSF specimens for PCR
analysis were collected at time of diagnosis and at each follow-up
visit. 200 ml of blood taken on heparin was mixed with an equal
volume of AS1 storage buffer (Qiagen, Germany). One ml of CSF
was centrifuged and the sediment was resuspended in 200 mlo f
AS1 buffer. Specimens were shipped at ambient temperature to
the Institute of Tropical Medicine Antwerp, Belgium (ITMA),
where DNA was extracted with the QIAamp DNA blood mini kit
(Qiagen, Germany). Blood of the healthy endemic controls was
collected, transported and extracted as described earlier [8]. DNA
extracts were stored at 220uC and analysed with a PCR targeting
a short sequence within the 18S ribosomal RNA gene of the
Trypanozoon. The 25 mL reaction mixture contained 16 PCR
buffer (Qiagen), 2.5 mM MgCl2 (Qiagen), 200 mM of each dNTP
(Roche), 0.8 mM of sense primer M18S-II-F-Tb (59-CGTAGTT-
GAACTGTGGGCCACGT-39) (Sigma), 0.8 mM of antisense
primer M18S-II-R-Tb (59-ATGCATGACATGCGTGAAAGT-
GAG-39) (Sigma), 2.5 mg acetylated bovine serum albumin
(Promega), 0.5 unit of HotStar Taq polymerase (Qiagen) and
2.5 ml of specimen DNA. An initial denaturation step of 94uC for
15 minutes to activate the HotStar Taq polymerase was followed
by 40 cycles of 94uC for 30 seconds, 60uC for 30 seconds and
72uC for 30 seconds and a final elongation step at 72uC for
5 minutes. Amplified products were analysed by electrophoresis in
a 2% agarose gel (Eurogentec) and U.V. illuminated (Syngene)
after ethidium bromide staining (Sigma). Measures to minimize
the risk of false positive results due to PCR contamination were
Author Summary
Post-treatment follow-up is crucial for sleeping sickness
patient management and still relies on microscopic
examination of the cerebrospinal fluid (CSF). Detection of
the parasites DNA with the polymerase chain reaction
(PCR) is proposed as a promising and possibly non-invasive
alternative for monitoring treatment outcome, but has
never been evaluated. We performed PCR on blood and
CSF of 360 Trypanosoma brucei gambiense sleeping
sickness patients, before treatment and during 2 years
after treatment, and on blood of 129 controls. We found
that performance of PCR to diagnose sleeping sickness
and detect brain involvement was better or similar to
current diagnostic techniques. However, we observed that
PCR was unreliable for monitoring treatment outcome.
Continued PCR positivity in cured patients points to
persistence of parasites, or their DNA, after successful
treatment, challenging the dogma that in sleeping
sickness cure equals parasite elimination. In conclusion,
we do not recommend PCR for treatment outcome
assessment in sleeping sickness.
PCR in HAT Follow-Up
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manipulations and inclusion of negative control samples during
DNA extraction and PCR. The person who performed and
interpreted the PCR results was a junior scientist experienced in
PCR, who was blinded to the results of the reference standard tests.
The analytical sensitivity of the PCR was evaluated using 10-
fold serial dilutions of T. b. gambiense procyclic parasites (strain
MBA) in 180 ml naı ¨ve human blood (ranging from 10,000 to 1
parasites) mixed with 180 mL AS1 lysis buffer (Qiagen, Germany).
The analytical specificity was assessed with purified DNA from
T. b. gambiense and T. b. rhodesiense (at 1 ng DNA per test) and from
Plasmodium falciparum, Leishmania donovani, T. cruzi, Mycobacterium
tuberculosis and Schistosoma mansoni (50 ng DNA per test).
Data analysis
STATA version 10 (Statacorp, USA) was used for data analysis
setting the level of significance at 0.05. Sensitivities and specificities
with 95% confidence intervals (CI) were calculated. Diagnosis of
treatment failure during follow-up implied exclusion from the
sensitivity calculations at subsequent time points. The Pearson’s chi-
square or Fisher exact test were performed to compare proportions
in different groups.
Results
Analytical sensitivity and specificity of the PCR
The PCR detected 1 parasite in a 180 ml blood sample while
non-spiked control blood samples remained negative. T. b.
gambiense and T. b. rhodesiense DNA was detected at 1 ng per test
while purified DNA from the non-target pathogens at 50 ng per
test did not generate a positive PCR signal.
HAT patients and healthy endemic controls
A flow diagram of the study participants is presented in figure 1.
Between January and September 2007, 129 healthy controls were
recruited of which 23 were in Mbuji-Mayi and 106 in Kinshasa.
Three hundred and sixty HAT patients were recruited between
May 2005 and May 2008, of which 41 were in first stage and 319
in second stage. There were 242 primary episodes of HAT, and
118 patients presented with a recurrence of HAT characterised by
trypanosome presence in CSF after unsuccessful previous
treatment for HAT. Treatment outcome was cure in 175 HAT
patients, while treatment failure occurred in 134. The number of
patients presenting and the number and type of treatment failures
diagnosed at each follow-up time point are shown in figure 1.
PCR analysis was performed between March 2006 and July 2009.
PCR on blood for diagnosis of HAT
Specificity of PCR on blood (PCR-blood) was 99.2% and the
sensitivity on primary HAT cases was 88.4% (table 1). The
sensitivity was not significantly different between primary stage 1
and 2 patients (p=0.184), but was significantly lower in
retreatment cases (p,0.001).
PCR on CSF for staging of HAT
The specificity of PCR on CSF (PCR-CSF) for disease staging
was 82.9% while the sensitivity was 88.4% (table 2). We did not
observe a difference in sensitivity of PCR-CSF between primary
and retreatment second stage patients (p=0.559).
PCR on blood for follow-up of HAT
In cured patients (table 3), the specificity of PCR-blood was
80.5% 3 months post-treatment, remained stable at a level of
89.9–92.4% between 6 and 18 months post-treatment to slightly
decrease to 81.2% 24 months post-treatment. Between 12 and 24
months after treatment, 24.6% (95% CI 18.1–31.0) of cured
patients had at least 1 PCR-blood positive result.
In patients that experienced treatment failure (table 3), the
sensitivity of PCR-blood was at a low level of 12.5% at 6 months
post-treatment and fluctuated between 20.0 and 50.0% later on.
PCR on CSF for follow-up of HAT
In cured patients (table 4), the specificity of PCR-CSF slowly
increased from 56.3% at 3 months after treatment to stagnate
between 79.7 and 83.7% from 12 months post-treatment until the
end of follow-up. Between 12 and 24 months post treatment,
35.4% (95% CI 28.3–42.6) of cured patients were CSF PCR
positive on at least one occasion when tested.
In patients that experienced treatment failure (table 4), the
sensitivity of PCR-CSF decreased from 72.2% at 3 months post-
treatment to 50% at the end of follow-up.
Discussion
In this study, PCR applied to blood for diagnosis of primary T.b.
gambiense HAT had 88% sensitivity and excellent specificity. For
staging, sensitivity of PCR on CSF was 88%, specificity 83%.
Sensitivity of PCR for detection of treatment failure during follow-
up was low in blood. In successfully treated patients, parasite DNA
disappeared only slowly from CSF, and remained detectable,
albeit intermittently, in around 20% of the cured patients until the
end of follow-up.
This is the first study in which PCR was performed
systematically over the complete 2 years post-treatment follow-
up of a large cohort of well characterised T.b. gambiense sleeping
sickness patients with known treatment outcome.
Several considerations need to be considered in evaluating the
data. For example, the patients enrolled in the cohort were a
mixture of primary and retreatment cases so the sensitivity of PCR
at diagnosis was estimated in primary cases only. Since patient
enrolment in the study required that parasites had been detected
by microscopic examination the sensitivity of PCR for HAT
diagnosis might be overestimated given that patients with relatively
high parasitemia were more likely to be included. Moreover,
patients were treated with 6 different treatment schedules [7] and
this may influence duration of PCR positivity after treatment,
although no obvious differences were observed between groups
(data not shown).
Follow-up examinations in the cohort focused on CSF
examination, and once trypanosomes had been detected in CSF
of relapsing patients, further blood examination was not carried
out for some patients. Most treatment failures were detected within
12 months after treatment, which decreased the power of the study
for reliable estimations of PCR sensitivity for treatment failure
later on. We opted to use primers targeting the 18S ribosomal
RNA gene, a multi-copy gene, offering high sensitivity given the
relatively low analytical sensitivity of current T.b. gambiense specific
PCR [13]. The M18S-II-Tb RNA gene primers will detect DNA
from other members of the Trypanozoon group, including the
closely related, but not pathogenic, T.b. brucei. Specificity of the
primer set was tested on purified DNA from non-target pathogens
and on blood of a control group, including endemic control
samples collected in the same laboratory in Mbuji-Mayi as the
HAT samples. A positive result in one of the uninfected control
subjects originating from Mbuji-Mayi might be attributable to
DNA from non-human infectious T. b. brucei in a tsetse bite. Since
overall DNA yield after extraction from the blood samples was not
PCR in HAT Follow-Up
www.plosntds.org 3 February 2011 | Volume 5 | Issue 2 | e972Figure 1. Classification of study participants according to reference standards for diagnosis, staging and follow-up (FU). At each
follow-up time point, the number of patients attending is given. Patient groups reaching a final outcome of treatment failure during follow-up and
excluded from analysis at subsequent time points, are indicated with an arrow.
doi:10.1371/journal.pntd.0000972.g001
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extraction cannot be excluded.
Specificity of PCR could not be tested on CSF of non-HAT
endemic controls given the ethical considerations in collecting CSF
from uninfected individuals.
For diagnosis of primary HAT, PCR on blood seems to show a
comparable sensitivity and similar high specificity as the
Trypanozoon OligoC-TesT targeting the same gene [8]. As such,
PCR performance compares favourably to the best parasite
detection techniques in current practice [14]. Given the technical
requirements for PCR, the approach cannot yet be recommended
for HAT patient diagnosis in the field [6]. However, it definitely
has potential in travel medicine clinics, as an alternative or
complement to the laborious microscopic techniques, and most
likely, is also interesting for epidemiological research.
PCR on CSF also has some potential for disease staging. The
observed sensitivity of CSF PCR is slightly lower than the 96–
100% observed earlier [15–17]. However, these studies applied
less sensitive trypanosome detection techniques and a primer set
(TBR 1–2) that might be more sensitive than the M18S-II-Tb
primers targeting the ribosomal RNA genes. Failure to diagnose
second stage HAT may have serious consequences for patients, as
most live in remote areas and might not get a second chance for
proper diagnosis and treatment. We observed positive PCR results
in CSF of some first stage patients, as has been reported previously
[16,17], apparently compromising specificity. Although if the
shortcomings of the actual reference standard for staging are taken
into account [4], the PCR approach might actually be demon-
strating better staging sensitivity than the classical staging
techniques [16]. The CSF-PCR positive first stage patients, with
one exception, were however successfully treated with pentami-
dine, confirming earlier findings [17]. Thus, positive PCR results
in otherwise normal CSF are to be interpreted with care.
The DNA detected in CSF could originate from parasites killed
in the blood, either by crossing the blood brain barrier or by
contamination during lumbar puncture, or from parasites that
died in the CSF, taking into account the unfavourable survival
conditions in that body fluid [18]. It could also originate from
trypanosomes that invaded the CSF without CNS injury or
inflammation and that are subsequently cleared with first stage
drugs [16,17]. The latter hypothesis is supported by reports of
sleeping sickness patients with normal white blood cell counts, but
with trypanosomes in CSF, that have been successfully treated
with pentamidine [19,20]. Interestingly, out of 11 second stage
patients with white blood cell counts between 6 and 20/mL and no
parasites observed in CSF, only 3 were positive in CSF-PCR (data
not shown). Although the sample number is too low to draw major
conclusions, this area of ambiguity, with few PCR positives,
confirms the limitations of using a cut-off of 5 white blood cells per
mL to make a diagnosis of stage 2 disease [4].
For patient follow-up after treatment, PCR on blood was
neither sensitive nor specific. Poor sensitivity of PCR on blood was
observed in the patients that were included in the study as
retreatment cases, and was confirmed during follow-up. Previous
studies [21] also indicated that PCR on blood is not an
appropriate technique for detection of treatment failure in T.
brucei infections. These observations further support the hypothesis
that relapses originate from the central nervous system [22], and
that trypanosomes are not likely to be found in blood of relapsing
patients [23]. Lack of specificity , i.e. detectable parasite DNA in
blood of some cured patients up to 24 months after treatment,
corroborates earlier observations in T.b. gambiense infected mice
where DNA was detected for a significant time period beyond
successful melarsoprol treatment [24]. Although we cannot
exclude the possibility that PCR-blood positivity among cured
patients is caused by tsetse bites contaminated with non-human
pathogenic T.b. brucei [25], this seems unlikely given the high
diagnostic specificity on the uninfected control subjects.
PCR on CSF to determine treatment outcome seems to be of
limited diagnostic value. Indeed, sensitivity of PCR on CSF for
Table 1. Sensitivity and specificity of PCR on blood for diagnosis of HAT.
Blood
Study cohort Number of specimens Number of positive PCRs Sensitivity % (95% CI) Specificity % (95% CI)
Control persons 129 1 99.2 (97.7–100)
All HAT patients 358 245 68.4 (63.6–73.3)
Primary HAT 242 214 88.4 (84.4–92.5)
Retreatment HAT 116 31 26.7 (18.6–34.8)
Note. CI=confidence interval.
doi:10.1371/journal.pntd.0000972.t001
Table 2. Sensitivity and specificity of PCR on CSF for staging of HAT.
CSF
Study cohort Number of specimens Number of positive PCRs Sensitivity % (95% CI) Specificity % (95% CI)
1
st stage HAT 41 7 82.9 (71.2–94.6)
2
nd stage HAT 318 281 88.4 (84.8–91.9)
Primary 2
nd stage 201 176 87.6 (83.0–92.2)
Retreatment 2
nd stage 117 105 89.7 (84.2–95.3)
Note. CI=confidence interval.
doi:10.1371/journal.pntd.0000972.t002
PCR in HAT Follow-Up
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PCR positive results in cured patients occurred even more
frequently than in blood. Two case reports on CSF-PCR positivity
after cure from T.b. gambiense infection have been published. Two
CSF samples taken at 4 and 14 months after eflornithine treatment
from a patient who was eventually cured, were positive in PCR
with TBR 1–2 primers [26]. Using the same primers, two cured
second stage patients out of a series of 15, were PCR positive in
CSF immediately and 1 month after treatment [15,27]. The
reason for persistent CSF-PCR positivity of some apparently cured
HAT patients remains obscure. Although not indicated by the
internal PCR controls, false positive test results due to carry-over
contamination can never be fully excluded. It may be also due to
DNA from killed trypanosomes stabilised in the form of immune
complexes [28] or in other ways and thus remaining detectable for
a long period even when the patient is cured. This is in contrast
with the finding that in herpes simplex viral encephalitis DNA
detected by nested PCR disappears from CSF within 20 days after
initiation of successful treatment [29]. Integration of T.b. gambiense
DNA sequences into the host genome is another possibility. For
example, spliced leader associated conserved DNA sequences of
T.b. brucei have been documented in hepatocytes and kidney tubule
cells of pentamidine treated, parasite negative, but intermittently
PCR positive rats [30]. Furthermore, kinetoplast minicircle DNA
from T. cruzi, a related kinetoplast causing American trypanoso-
miasis, has been shown to integrate into the human genome [31].
PCR positive results during follow-up might also point to the
presence of living trypanosomes, i.e. continued brain infection,
although patients were declared cured from the disease 2 years
after treatment. This might underline a possible need to
differentiate between parasitological and clinical cure. Indeed,
some T.b. gambiense isolates do induce silent infections in the brains
of mice that survived without clinical signs and without detectable
parasites for more than 12 months, but with fluctuating PCR
positivity [32]. In the same way, low amounts of DNA that
fluctuate above and below the PCR detection limit may underlie
the observed intermittent positivity in PCR results in the patient
cohort studied here. Persistent silent T.b. gambiense infection even
with treatment, could be explained by parasites residing in
pharmacologically privileged sites (for example within host cells or
in organs or tissues with reduced drug accessibility). Using in vitro
models, the presence of T.b. brucei within astrocytes and entry of
T.b. gambiense into microvascular endothelial cells of the human
blood-brain barrier have been claimed [33,34]. Persistence of T.b.
brucei in the testis has also been shown in a mouse model after
suboptimal drug dosage [35].
Our findings have important clinical implications for patient
follow-up after treatment. While new algorithms based on
normalised white blood cell count and the absence of trypano-
somes in CSF may allow for cessation of follow-up at 6 months for
the majority of patients [7], PCR on CSF remains positive in a
significant fraction of the cured patients. A role of PCR or other
Table 3. Specificity and sensitivity of PCR on blood during post-treatment follow-up.
Blood
Cured patients Patients with treatment failure
FU time point
Number of
specimens
Number of
positive PCRs
Specificity %
(95% CI)
Number of
specimens
Number of
positive PCRs
Sensitivity %
(95% CI)
Pre-treatment 174 101 42.0 (34.6–49.3) 134 109 81.3 (74.7–88.0)
3 months 169 33 80.5 (74.5–86.3) 126 27 21.4 (14.2–28.7)
6 months 168 17 89.9 (85.3–94.5) 80 10 12.5 (5.2–19.8)
12 months 157 12 92.4 (88.2–96.6) 27 8 29.6 (12.0–47.3)
18 months 132 10 92.4 (87.9–97.0) 10 2 20.0 (0–46.4)
24 months 160 30 81.2 (75.1–87.4) 4 2 50 (0.0–1.0)
Note. CI=confidence interval.
doi:10.1371/journal.pntd.0000972.t003
Table 4. Specificity and sensitivity of PCR on CSF during post-treatment follow-up.
CSF
Cured patients Patients with treatment failure
FU time point
Number of
specimens
Number of
positive PCRs
Specificity %
(95% CI)
Number of
specimens
Number of
positive PCRs
Sensitivity %
(95% CI)
Pre-treatment 174 126 27.6 (20.9–34.3) 134 119 88.8 (83.4–94.2)
3 months 167 73 56.3 (48.7–63.9) 126 91 72.2 (64.3–80.1)
6 months 168 63 62.5 (55.1–69.9) 80 55 68.8 (58.5–79.0)
12 months 157 27 82.8 (76.8–88.8) 27 17 63.0 (44.3–81.6)
18 months 129 21 83.7 (77.3–90.2) 10 4 40.0 (7.7–72.3)
24 months 158 32 79.7 (73.4–86.1) 4 2 50 (0.0–100.0)
Note. CI=confidence interval.
doi:10.1371/journal.pntd.0000972.t004
PCR in HAT Follow-Up
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therefore is questionable. Fearing the repeated lumbar punctures
during follow-up, most patients stay away from post-treatment
controls [23,36,37]. PCR on blood has been proposed as a non-
invasive alternative to replace the invasive CSF examination, but
this is not supported by our results.
Confirmation of the results on other patient cohorts using other
PCR primer sets or other DNA detection methods such as loop
mediated isothermal amplification would be desirable [38]. If
persistence of DNA or parasites in clinically cured patients is
confirmed, it will be valuable to verify with quantitative real-time
PCR if the DNA concentration in CSF correlates to treatment
outcome. Clearly more work will be needed to fully understand the
biological mechanism of DNA or parasite persistence and the
dogma that cure equals parasite elimination may need revision.
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